Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the
“Company”), a clinical-stage biotechnology company developing
biologics intended to enhance regulatory T cell (Treg) function,
announces that CEO Howard Berman, Ph.D. will present at two
upcoming healthcare conferences.
On September 26, 2024, Dr. Berman will participate in a panel
discussion at Munsch Hardt’s 3rd Annual Texas Health Care
Transactions Conference being held at the Houstonian Hotel in
Houston, Texas. The panel is titled, “Affiliations with Hospital
Systems: Exploring Paths to Collaboration and M&A,” and will
begin at 1:15pm CT. This conference aims to connect more than 250
executives and thought leaders across today’s rapidly evolving
health care industry, including top executives, practitioners,
consultants, private equity investors, and venture capitalists.
Investors can register here for the conference and gain access to
this panel discussion.
On October 28, 2024, Dr. Berman and Dr. Stanley Appel, Chairman
of Coya’s Scientific Advisory Board, will present at the inaugural
Alzheimer’s Drug Discovery Foundation (ADDF) Summit: Advancements
in Novel Therapeutics and Combination Therapy being held in Madrid,
Spain at the Marriot Auditorium Hotel & Conference Center. At
the summit, Drs. Berman and Appel will present data on COYA 302 and
the role of Tregs in neurodegeneration. The summit is being held in
alignment with the 2024 Clinical Trials on Alzheimer’s Disease
(CTAD) conference also being held in Madrid at the same venue and
being held from October 29 – November 1, 2024. The Company
previously announced that results from a Gates Foundation and
Alzheimer’s Association funded double-blind, placebo-controlled
study in 38 patients with mild-to-moderate Alzheimer’s disease
treated with low-dose interleukin-2 (LD IL-2) will be presented at
CTAD by Dr. Alireza Faridar, Professor of Neurology at Houston
Methodist and principal investigator, and will help guide further
clinical development of COYA 302 for the treatment of Alzheimer’s
disease.
The ADDF Summit is an invite-only event that convenes and
connects Alzheimer’s experts across the field who are focused on
developing cutting edge new treatments under the biology of biology
framework with the end goal of advancing the field towards a
combination therapy and precision medicine approach. This event is
a full-day, interactive collaboration of scientists, academia,
industry and government professionals, and other pioneers who are
passionate about advancing the path to a cure and will consist of
scientific presentations, panel discussions, and a keynote
session.
In May 2024, the Company received a $5 million strategic equity
investment from the ADDF to support the development of COYA 302 for
the treatment of Frontotemporal Dementia (FTD). COYA 302’s
combination therapeutic approach aligns with the ADDF’s belief in
combination therapy being the future of treatment for Alzheimer’s
disease and related dementias.
About Coya Therapeutics, Inc.
Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq:
COYA) is a clinical-stage biotechnology company developing
proprietary treatments focused on the biology and potential
therapeutic advantages of regulatory T cells (“Tregs”) to target
systemic inflammation and neuroinflammation. Dysfunctional Tregs
underlie numerous conditions, including neurodegenerative,
metabolic, and autoimmune diseases, and this cellular dysfunction
may lead to sustained inflammation and oxidative stress resulting
in lack of homeostasis of the immune system.
Coya’s investigational product candidate pipeline leverages
multiple therapeutic modalities aimed at restoring the
anti-inflammatory and immunomodulatory functions of Tregs. Coya’s
therapeutic platforms include Treg-enhancing biologics,
Treg-derived exosomes, and autologous Treg cell therapy.
COYA 302 – the Company’s lead biologic investigational product
or “Pipeline in a Product”– is a proprietary combination of COYA
301 (Coya’s proprietary LD IL-2) and proprietary CTLA4-Ig fusion
protein (in-licensed from Dr. Reddy’s Laboratories) for
subcutaneous administration with a unique dual mechanism of action
that is now being developed for the treatment of Amyotrophic
Lateral Sclerosis, Frontotemporal Dementia, Parkinson’s Disease,
and Alzheimer’s Disease. Its multi-targeted approach enhances the
number and anti-inflammatory function of Tregs and simultaneously
lowers the expression of activated microglia and the secretion of
pro-inflammatory mediators. This synergistic mechanism may lead to
the re-establishment of immune balance and amelioration of
inflammation in a sustained and durable manner that may not be
achieved by either low-dose IL-2 or CTLA4-Ig alone.
For more information about Coya, please visit
www.coyatherapeutics.com
Forward-Looking Statements
This press release contains “forward-looking” statements that
are based on our management’s beliefs and assumptions and on
information currently available to management. Forward-looking
statements include all statements other than statements of
historical fact contained in this presentation, including
information concerning our current and future financial
performance, business plans and objectives, current and future
clinical and preclinical development activities, timing and success
of our ongoing and planned clinical trials and related data, the
timing of announcements, updates and results of our clinical trials
and related data, our ability to obtain and maintain regulatory
approval, the potential therapeutic benefits and economic value of
our product candidates, competitive position, industry environment
and potential market opportunities. The words “believe,” “may,”
“will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,”
and similar expressions are intended to identify forward-looking
statements.
Forward-looking statements are subject to known and unknown
risks, uncertainties, assumptions and other factors including, but
not limited to, those related to risks associated with the impact
of COVID-19; the success, cost and timing of our product candidate
development activities and ongoing and planned clinical trials; our
plans to develop and commercialize targeted therapeutics; the
progress of patient enrollment and dosing in our preclinical or
clinical trials; the ability of our product candidates to achieve
applicable endpoints in the clinical trials; the safety profile of
our product candidates; the potential for data from our clinical
trials to support a marketing application, as well as the timing of
these events; our ability to obtain funding for our operations;
development and commercialization of our product candidates; the
timing of and our ability to obtain and maintain regulatory
approvals; the rate and degree of market acceptance and clinical
utility of our product candidates; the size and growth potential of
the markets for our product candidates, and our ability to serve
those markets; our commercialization, marketing and manufacturing
capabilities and strategy; future agreements with third parties in
connection with the commercialization of our product candidates;
our expectations regarding our ability to obtain and maintain
intellectual property protection; our dependence on third party
manufacturers; the success of competing therapies or products that
are or may become available; our ability to attract and retain key
scientific or management personnel; our ability to identify
additional product candidates with significant commercial potential
consistent with our commercial objectives; and our estimates
regarding expenses, future revenue, capital requirements and needs
for additional financing.
We have based these forward-looking statements largely on our
current expectations and projections about future events and trends
that we believe may affect our financial condition, results of
operations, business strategy, short-term and long-term business
operations and objectives, and financial needs. Moreover, we
operate in a very competitive and rapidly changing environment, and
new risks may emerge from time to time. It is not possible for our
management to predict all risks, nor can we assess the impact of
all factors on our business or the extent to which any factor, or
combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements
we may make. In light of these risks, uncertainties and
assumptions, the forward-looking events and circumstances discussed
herein may not occur and actual results could differ materially and
adversely from those anticipated or implied in the forward-looking
statements. Although our management believes that the expectations
reflected in our forward-looking statements are reasonable, we
cannot guarantee that the future results, levels of activity,
performance or events and circumstances described in the
forward-looking statements will be achieved or occur. We undertake
no obligation to publicly update any forward-looking statements,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240903169834/en/
Investor Contact David
Snyder, CFO david@coyatherapeutics.com CORE IR Bret Shapiro
brets@coreir.com 561-479-8566 Media
Contacts For Coya Therapeutics: Kati Waldenburg
media@coyatherapeutics.com 212-655-0924
Grafico Azioni Coya Therapeutics (NASDAQ:COYA)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Coya Therapeutics (NASDAQ:COYA)
Storico
Da Nov 2023 a Nov 2024
